Aura Biosciences Inc (AURA)

Aura Biosciences Inc is a pioneering clinical-stage biotechnology company focused on transforming cancer treatment through its unique virus-like particle (VLP) technology. The company’s lead investigational therapy, AU-011, specifically targets ocular cancer cells, striving to eliminate tumors while safeguarding surrounding healthy tissue—demonstrating a commitment to precision oncology. With a robust pipeline designed to address critical unmet needs in cancer care and a highly experienced management team, Aura is strategically positioned to make significant advancements in the oncology market. Furthermore, its collaborative approach enhances innovation potential and aligns with the sector's growing demand for targeted therapies.